Refining Analytical Tools to Better Characterize Drug Products & Future-Proof Automated Analytical Development to Speed Up Product Release & Treat More Patients
December 4-6, 2023 | Boston, MA
Welcome to the 5th Cell Therapy Analytical Development Summit
Analytical development remains a critical component of the drug development landscape, but lengthy production timelines mean that automating analytical processes and expediting release times remain a key priority.
Returning for the 5th year, the Cell Therapy Analytical Development Summit will unite technical leaders to better characterize potency, safety, viability, and sterility across early and late-stage analytical development for oncology & regenerative medicine.
New for 2023, attend with your team to cover the 3 tracks of content showcasing the most important advances across immunophenotype assays, molecular assays, and cell-based assays. Brainstorm and share case studies with industry leaders from Kite Pharma, Takeda, and Bristol Myers Squibb on best practices for optimizing release testing, meeting regulatory requirements, and developing phase appropriate tools to match manufacturing timelines using automation.
As the field moves away from standard CAR-T constructs, assess the additional complexities faced when developing Gamma Delta, NK-based, and iPSC-derived products and novel engineering approaches.
This is the most critical meeting in the calendar for Analytical Developers and Quality Control Experts - we can’t wait to welcome your team in December!
"A breakthrough summit that enables a discussion on emerging needs in the analytical development arena.”
Scientist, CRISPR Therapeutics
Don't Miss Your Chance To:
Collaborate and exchange insights with those pioneering cell therapy analytical development for CAR-T drug products and beyond, including Kite Pharma, Takeda, Century Therapeutics and Arsenal Bio.
Explore brand new sessions dedicated to the nuances with analytical development for iPSC-derived, NK and gamma delta products and assay qualification and validation for regenerative medicine to reflect the expansion of cell therapies beyond CAR-T constructs
Dive into the additional complexities for characterizing gene-edited products and drug substances such as viral vectors for comprehensive safety testing of your product
Advance your analytical program and discover best practices to optimize release testing, adapt to evolving regulatory requirements, and develop phase-appropriate tools.
Leverage strategical case studies for developing standardized platforms to transform manual flow assays to automated processes to streamline vein-to-vein processes
Previously Attending Companies:
Companies On The Program:
"The Cell Therapy Analytical Development Summit is a highly effective platform for all players in the field of cell and gene therapy to come together and share knowledge, experiences, and learnings to advance the field together. New players can explore and learn from more experienced players and pioneers who have paved the way. There is a lot for everyone to take home, even the experienced players, as the field is rapidly evolving and the landscape constantly changing.”
Senior Director, Department of Chemistry, Manufacture and Control (CMC), Immatics